Loading clinical trials...
Loading clinical trials...
This phases Ⅲ trials is divided into two stages,Ⅲa and Ⅲb.The aim of Ⅲa is to evaluate the optimal dosing dose of genetically modified recombinant human IL-11 (mIL-11) in a multicenter randomized self...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Beijing Northland Biotech. Co., Ltd.
NCT07492693 · Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors
NCT07063225 · Chemotherapy-induced Thrombocytopenia, Romiplostim N01
NCT05236582 · Chemotherapy-induced Thrombocytopenia, Herombopag
NCT05864014 · Chemotherapy-Induced Thrombocytopenia
NCT07647029 · Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
Beijing Cancer Hospital
Beijing, Beijing Municipality
The Third Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang
The First Hospital of Jilin University
Changchun, Jilin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions